Clinical trial Recruiting at 3 sites Observational Ages 40 and up

Follow-up after COPD exacerbation

Official title: A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization

Run by Viz.ai, Inc. · NCT07118306 · Data updated 2026-11-12

This project will try an AI-enabled workflow tool (Viz COPD) to see if it increases respiratory specialist follow-up and improves outcomes after a COPD flare-up in patients seen in the emergency department.

Quick facts

Study typeObservational
Ages40 Years and up
SexAll
Enrollment485 (estimated)
SponsorViz.ai, Inc.
Industry-sponsored
Locations5 sites (Park Ridge, Illinois and 4 other locations)
StatusRecruiting
StartedFebruary 27, 2026
Main results expectedJuly 2027
Study endsDecember 2027
Registry record updatedSeptember 2, 2026
Trial IDNCT07118306 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 40 or older with a clinical diagnosis of COPD who present to the emergency department with a moderate or severe exacerbation and who are on dual or triple long-acting bronchodilator inhaler therapy.

Probably not a fit

Patients unlikely to benefit include those on bronchodilator monotherapy, with tracheostomy, advanced cancer, prior lung transplant, discharged to hospice, those who left against medical advice, or who died during hospitalization.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares patients exposed to an AI-enabled clinical workflow tool (Viz COPD) with a historical control cohort to measure respiratory specialist follow-up and downstream clinical outcomes after an acute COPD exacerbation. The Experimental cohort is collected prospectively with the tool active, the Control cohort is retrospective, and an Exploratory cohort includes both retrospective and prospective data. Primary outcomes include rates and timing of specialist follow-up, rehospitalizations, emergency visits, and mortality within a defined follow-up window. Data are gathered from electronic health records and workflow logs without changing standard clinical treatments.

Why it matters

Potential benefit: If successful, this could increase timely specialist follow-up after COPD exacerbations and reduce readmissions and other adverse outcomes.

How similar studies have gone: Related AI-enabled workflow tools have improved timeliness of specialist notification in acute conditions like stroke, but applying this approach specifically to COPD exacerbation follow-up is relatively novel with limited published evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients aged 40 years or older at the time of arrival to the emergency department.
* Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
* A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
* A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for \>24 hours in emergency department/urgent care facility or resulting in death.
* Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.

Exclusion Criteria:

* Patients on bronchodilator inhaler monotherapy.
* Patients leaving against medical advice or expiring during hospitalization.
* Patients with tracheostomy.
* Patients with advanced cancer.
* Patients who have received a lung transplant.
* Discharge to hospice care.
* Transfer to another hospital.

Where it's running

  • Advocate Lutheran General Hospital
    Park Ridge, Illinois, United States
    Recruiting
  • Cooper University Health Care
    Cherry Hill, New Jersey, United States
    Recruiting
  • Thomas Jefferson University
    Philadelphia, Pennsylvania, United States
    Recruiting
  • Inova Fairfax Hospital
    Falls Church, Virginia, United States
    Not yet recruiting
  • Aurora St. Luke's Medical Center
    Milwaukee, Wisconsin, United States
    Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.